Basket Trials (as of February 2024)

ENGOT-GYN5/NCRI/NXP800-101

Leading group: NCRI

Clinical Trial Study: A Phase I/II Clinical Study of NXP800 in Subjects with Advanced Solid Tumors

Planned number of patients: 40

Participating groups: TBD

 

ENGOT-GYN4/NOGGO/EXPRESSION IX

Leading group: NOGGO

Clinical Trial Study: Expression IX-Longterm survival with gynecological cancer

Planned number of patients: 1000 (100-200 per country)

Participating groups: BGOG, A-AGO, MITO, TRSGO, NSGO, SwissGO, CEEGOG, ANZGOG

 

ENGOT-GYN3/AGO/LIO

Leading group: AGO

Clinical Trial Study: LIO-1: A phase 1b/2, open-label study to evaluate the safety and efficacy of lucitanib in combination with nivolumab in patients with an advanced, metastatic solid tumor

Planned number of patients: 161

Participating groups: BGOG, GEICO, MITO, NOGGO

 

ENGOT-GYN2/GINECO/BOUQUET

Leading group: GINECO

Clinical Trial Study: A multicenter, multi-arm, open-label, genomics-driven phase II study evaluating the clinical benefit of molecularly targeted therapies alone or in combination in patients with progressive locally-advanced or metastatic rare gynecologic tumors after one line of systemic therapy

Planned number of patients: 20 patients per cohort

Participating groups: AGO, BGOG, CEEGOG, GEICO, MITO, MaNGO, Swiss GO, TRSGO, NCRI 

 

ENGOT-GYN1/NCRI/ATARI

Leading group: NCRI

Clinical Trial Study: ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss  

Planned number of patients: 116

Participating groups: GINECO, Princes Margaret Consortium Canada

Next ENGOT meeting

April 3-4, 2025

Nice, France

 

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

ESGO_Rome_Website_1200x627

ESGO 2025

February 20-23, 2025
Rome, Italy

 

Read More